Quality Control of Electronic Pathology (E-Path)ResultsPeriod of Performance: September 15, 2014 - September 14, 2015

电子病理质量控制（E-Path）结果执行期间：2014年9月15日-2015年9月14日

• 批准号: 8947591
• 负责人: VIVIEN CHEN
• 金额: $ 16.38万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-12 至 2015-09-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8947591
• 关键词: Addendum; Adherence; Age Factors; BRAF gene; Breast; Cancer Center; Colorectal; Colorectal Cancer; Databases; Diagnosis; ERBB2 gene; Electronics; Gold; Guidelines; Insurance; KRAS2 gene; Louisiana; Molecular; Mutation; National Comprehensive Cancer Network; Pathology; Pathology Report; Patients; Performance; Poverty; Public Hospitals; Quality Control; Race; Records; Registries; Reporting; Teaching Hospitals; Test Result; Testing; malignant breast neoplasm; overexpression; quality assurance; tumor registry

LSU will assess quality and completeness of electronic pathology (E-Path) results for colorectal cancer and breast cancer. LSU will collect electronic pathology results for KRAS mutation test results from colorectal cancer case records, and will collect HER2 results from breast cancer case records. LSU will assess the completeness of these records and document compliance with recommended testing.

路易斯安那州立大学将评估结直肠癌和乳腺癌的电子病理学 (E-Path) 结果的质量和完整性。 LSU 将从结直肠癌病例记录中收集 KRAS 突变检测结果的电子病理结果，并将从乳腺癌病例记录中收集 HER2 结果。路易斯安那州立大学将评估这些记录的完整性并记录是否符合建议的测试。